ATF5 and glioblastoma: A chemically synthesized variant of this dominant-negative peptide, termed CP-d/n-ATF5-S1, was shown to elicit a significant apoptotic response in culture and inhibit growth of treatment-resistant glioblastoma xenografts, though tumor regression was not observed [56].